(UBS) European Auto Suppliers : Continental Upgraded to Buy

European Auto Suppliers - What are the implications of the China slowdown?

* Reducing global production; UBS interactive model on China now available
We reduce our global production forecasts from +1.7% to +0.7% in '15 and from +3.7% to 2.6% in
'16, mainly driven by China. Given the higher level of inventories in July and longer summer breaks, we
expect no H2 production growth in China. We also anticipate the Domestic OEMs will continue to
outperform the JVs near term. We reduce our FY '16 production forecasts from +7% to +5%, with
domestic +10% and JV up +2%. We introduce our interactive model, which looks at 11 global suppliers
and enables us to gauge the impact of production growth (from each Domestic OEMs and JVs) and
currency on the suppliers' organic growth, customer mix, group sales/profitability. We have built in three
scenarios: UBS base case; downside case (domestic OEMs gain share); upside case (JVs regain share).

* The right "recipe": product mix, domestic OEMs exposure and aftermarket
We identify the best positioned suppliers in China as those with 1) strong product mix contribution/high
content value, 2) higher exposure to domestic OEMs and 3) aftermarket. In our downside case, where
China production grows by "only" 2% next year, we estimate the impact on group EBIT will range from
-1/-3% (Valeo, Conti, Autoliv) to -16% (Faurecia) (vs UBS base case). With share prices declining 15-30%
vs peak and assuming no change in multiples, we would need China production to decline c20% this
year and next to reflect a similar impact at the EBIT level, which seems an overly pessimistic outcome, in
our view.

* FX: mostly naturally hedged; main issue is potential impact on German exports
The RMB depreciation should not have a material impact since suppliers are mostly naturally hedged. We
estimate that a 5% RMB devaluation translates into a -1/-2% impact on sales/profitability. However, the
impact on exports from Germany is more worrying (high content value) since c5% of German
production is exported to China.

* Upgrading Conti to Buy; Valeo remains a Top Pick; Faurecia most at risk
We upgrade Conti to Buy on: 1) earnings visibility and resilience, 2) Tires margin staying at high level for
longer, 3) limited China risk (diluted by Rubber exposure), 4) Best-in-class cash conversion. Valeo's share
price has over-reacted, in our view: business model is resilient, organic growth should remain best-inclass
and there is high FCF potential near term. Faurecia appears most at risk of a China slowdown and
there is limited margin momentum left. Autoliv has limited downside risk to China (lower base, high
exposure to Domestic OEMs) but valuation still high given lack of margin momentum.

>>> Europe : Brokers Upgrades & Downgrades - 3rd of September 20

>>> Up
*ACERINOX RAISED TO BUY VS HOLD AT JEFFERIES
*ASSA ABLOY RAISED TO BUY VS HOLD AT SOCIETE GENERALE
*ATLAS COPCO RAISED TO BUY AT NORDEA
*AUTOGRILL RAISED TO BUY VS HOLD AT KEPLER CHEUVREUX
*BANKIA RAISED TO NEUTRAL VS UNDERPERFORM AT CREDIT SUISSE (note attached)
*CONTINENTAL AG RAISED TO BUY VS NEUTRAL AT UBS
*FRESENIUS MEDICAL CARE RAISED TO BUY VS NEUTRAL AT GOLDMAN
*HERMES RAISED TO OUTPERFORM VS SECTOR PERFORM AT RBC
*MORRISON RAISED TO NEUTRAL VS SELL AT UBS
*RECKITT BENCKISER RAISED TO OVERWEIGHT VS NEUTRAL AT JPMORGAN
*SUBSEA 7 RAISED TO HOLD VS REDUCE AT HSBC
*TALKTALK RAISED TO NEUTRAL AT EXANE BNP PARIBAS
*TOTAL RAISED TO BUY VS NEUTRAL AT ODDO
*VIRGIN MONEY RAISED TO BUY VS HOLD AT INVESTEC

>>> Down
*CGG CUT TO HOLD VS BUY AT HSBC
*EASYJET CUT TO NEUTRAL VS BUY AT UBS
*ENGIE CUT TO UNDERPERFORM VS NEUTRAL AT BOFA
*DRAX CUT TO UNDERPERFORM VS NEUTRAL AT BOFA
*OPTIMAL PAYMENTS RATED NEW BUY AT CITI; PT 400P
*SABADELL CUT TO UNDERPERFORM VS OUTPERFORM AT CREDIT SUISSE (NOte Attached)
*SALZGITTER CUT TO UNDERPERFORM VS HOLD AT JEFFERIES

>>> PT Change
*VIVENDI PT RAISED FROM €20.50 TO €21 AT BARCLAYS ( Note attached)

>>> Initiation
*SENIOR RATED NEW BUY AT BERENBERG; PT 320P
*WIZZ AIR RATED NEW BUY AT UBS, PT 2,200P

>> Call
>> Stock
*AEROFLOT REMOVED FROM GOLDMAN CEEMEA FOCUS LIST
*EUROPCAR ADDED TO GOLDMAN CONVICTION BUY LIST
>> Sector
* European Luxury : Beware of wholesale destocking (Note /attached)
* Consumer : Berenberg September Update (Note /attached)

>>> What to look at today - 3rd of September 2015

Dow+1.82% S&P+1.63% Nasdaq+2.46% Russell+1.48% VIX 26.09 (-16.91%)
US MArket closed higher, after testing the 1,900 suoport yest., market didn't managed to break the 1.50 resistance ahead of tomorrow emplyment report. Chinese market is closed for 2 days for victyory day, this can also helped US to perform. Technology continiue to lead the move with all big gap up between 2.3% and 4.3%...financials continue to trade below market. Crude continue to be very volatile, ending the pit session higher by 1.9% at $46.25/bbl after testing the $43.22/bbl area. WTI crude slumped to lows after the latest inventory report showed a larger than expected build while news that Senate has enough votes to back the Iran nuclear deal also contributed to the brief weakness in oil. Volume were below average. US After Hours SEAC +4.5%, OOMA +2.2%, FIVE -9.5%, VRNT -6.4% following earnings/guidance...GERN+20% on +ve article on drug, LCI +18% to acquire Kremers Urban Pharmaceuticals for $1.23 bln; expects the deal to be accretive to adjusted EPS in FY16 in the mid-high single digits and 20-25% in FY17...Asian Market less voaltile on Chinese holidays for commemoration of WWII...Markets are waiting for ECB update & NFP...US financial press report citing sources close to the IMF suggested the FX reform by the PBoC could make the IMF more inclined to include it in the SDR basket. Recall on Aug 19th, IMF board announced it would extend SDR rights basket through Sept of 2016, deferring on the decision for including Yuan until the end of this year. Also of note on the IMF, its report to G20 warned that China slowdown could be larger than expected and is among primary risks to global growth outlook. IMF also called for a "mutual" (coordinated) policy action to raise growth and mitigate risks, specifically asking for assistance from surplus economies such as Germany.

Nikkei +0.69% Hang Seng & Shanghai Closed today & Tomorrow for WW2 comm.

Eur$ 1.1227 CNY 6.3559 JPY 120.45 EURCHF 1.0882 GBP 1.5294 RUB$ 66.7998 WTI $46.12 (-0.28%)

S&P +0.13% (Testing Support levels watch the 1950/1955 levels on the Cash) EuroStoxx +0.53% Dax +0.63% SMI +0.39%

Macro :
- Investors Withdraw Most From U.S. Mutual Funds Since June 2013
- Nikkei Japan Aug. Composite PMI 52.9 vs 51.5 in July
- Draghi Seen Sharpening Language as ECB Fights Fading Inflation
- Pimco Total Return Falls Below $100 Billion, a Third of Peak
- India Rate Cut Now a Question of When, Not If, For Rajan

Keep an eye on :
- ACS SM : ACS Could Claim EU300M From Spain Govt for TP Ferro: Economista
- AGL IM : Unipol Enters FTSE MIB Index, Replacing Autogrill
- AF FP : Air France Considers Entering Low-Cost Long-Haul, Les Echos Says
- ALV GY : Allianz Sees Industrial Insurances Rising, Boersen-Zeitung Says
- ALT FP : Altran 1H Net Income Rises 34%; Sees Profitable Growth for 2015
- BAS GY : For BASF, Huge Potential Liability Emerges Years After Takeover
- BKT SM : Bankinter to Buy Barclays Portugal Retail Unit for About EU100M
- CBK GY : Commerzbank Still Plans to Pay Dividend in 2016: Handelsblatt
- AM FP : France Could Sell Rafale to India, Malaysia Soon: L’Opinion
- EDF FP : Start-Up of Flamanville EPR Reactor Delayed: Le Figaro
- EVE SW : Evolva Planned Rights Offering for 62.4m New Registered Shares
- EVK GY : Institutional Investor Selling 6.99m Evonik Shares, Terms Show
- HEI GY : HeidelbergCement syndicates bridge financing for Italcementi acquisition, completes disposal of lime business in Germany
- III LN : 3I Said in Talks About Strategic Review of Mayborn Group: Sky
- ISS LN : Ontario Teachers Selling 11m ISS Shares in Bookbuild: Terms
- LHN VX : LafargeHolcim to Pay Scrip Dividend of 1 Share for 20 Held
- MGN GY : U.S.-Patent Office Grants Patent for Mologen MGN1703 Therapy
- PGIL LN : Wandle Considering Buying Rest of Polyus Gold for $2.97/Shr
- RIO LN : KKR Interested in Rio Tinto’s Hunter Valley Coal: Australian
- SYNN VX : Syngenta Plans Buyback ($2bil) , Aims to Divest Global Vegetables Seeds
- TRE SM : Two Groups Emerge as Frontrunners for Saudi Aramco Project: DJ
- TIT IM : Vivendi Has Begun Informal Talks With Telecom Italia, CEO Says
- UNI IM : Unipol Enters FTSE MIB Index, Replacing Autogrill
- VIV FP : Vivendi 2Q Sales Beat, Adj. Net Income Misses Ests.
- VIV FP : Bollore to Take Over as Head of Canal+, Les Echos Says
- VIV FP : Apple Music Is ‘Model of the Future’, Universal Music Owner Says
- VIV FP : Vivendi in exclusive talks to become minority partner in Banijay/Zodiak merged entity ( new group will be the world's third largest producer of entertainment programming)
- YOOX IM : Net-a-Porter’s Founder Massenet Said to Quit Online Retailer

>>> Syngenta to sell vegetable seeds business and repurchase shares

Syngenta to sell vegetable seeds business and repurchase shares
Syngenta [NYSE:SYT], the Swiss agribusiness company, announced plans to divest its vegetable seeds business and launch a share repurchase program, according to a September 3 company statement.

The main points from the release break down as follows:

Syngenta has announced its intention to divest its global vegetables seeds business. This business has a significant global footprint and a wide array of best-in-class varieties. As such, it is expected to attract significant third-party interest.

The company also announced its intention to return significant levels of capital to shareholders through a share repurchase program. The initial program of more than USD 2bn will commence in the coming weeks. This will be in addition to the progressive dividend policy which the company has followed for several years.

Michel Demaré, Chairman, said: “The Board and management are determined to accelerate shareholder value creation and our actions today underpin our commitment to do so. Our commitment is also shown by the significant capital return program that we announced today.”

Mike Mack, Chief Executive Officer, said: “By demonstrating and unlocking the inherent worth of our leading global seeds portfolio we can create significant additional value. I look forward to updating shareholders in the coming months on progress, including providing further visibility on the underlying profitability of our portfolio of assets.

“We continue to make excellent progress with our AOL program which, together with our clear intent to drive margin improvement across the business, underpins our confidence in our 2018 margin target of 24-26%. For 2015 we reiterate the full year guidance that we outlined in July.”

(BN) For BASF, Huge Potential Liability Emerges Years After Takeover


For BASF, Huge Potential Liability Emerges Years After Takeover
2015-09-03 04:00:01.11 GMT


By Jef Feeley and David Voreacos
(Bloomberg) -- When BASF SE acquired Engelhard Corp. nine
years ago for $5 billion, executives unknowingly inherited a
ticking legal time bomb.
It all began decades ago over the seemingly mundane
industrial product talc, used in everything from wallboards to
handling auto tires on the factory line.
In 1983, Engelhard quietly settled a lawsuit after its
officials testified in depositions that talc produced by a
company mine contained cancer-causing asbestos. All evidence was
sealed and Engelhard and its law firm repeatedly said in
subsequent lawsuits spanning more than two decades that the
company’s talc was asbestos-free.
It wasn’t until 2009, after BASF assumed Engelhard’s
liabilities, that another picture began to emerge. A former
Engelhard scientist testifying in a lawsuit filed by his own
daughter said he was told that “asbestos in trace amounts was
found in talc,” and the company’s legal department “told us to
purge our records” relating to the mine. A co-worker testified
about test results in the 1970s showing the presence of asbestos
in the talc.
Those revelations pulled back the curtain after a quarter
century, setting off a fight over what Engelhard knew about its
talc, how its lawyers may have acted and whether thousands of
people around the U.S. should have the right to reopen or bring
new lawsuits, this time against BASF, for asbestos illnesses. It
also raises fundamental questions about whether justice is
possible if companies and lawyers hide evidence in civil
litigation.
“This has really opened a Pandora’s Box,” said Tom Bevan, a
lawyer in Boston Heights, Ohio, who represented hundreds of
people who sued Engelhard in the 1990s and is involved in a
current federal case against BASF. “I wouldn’t want to be a BASF
shareholder right now with potentially billions of dollars in
liability coming down the pike because of the lies of a company
it bought.”

Distance Itself

BASF, based in Ludwigshafen, Germany, faces about 300
lawsuits related to the talc. The company, which is the world’s
largest chemical maker and had $74.3 billion in revenue last
year, has tried to distance itself from the alleged behavior of
Engelhard and its former law firm, Cahill Gordon & Reindel LLP.
Plaintiffs’ lawyers say as many as 10,000 potential cases
related to Engelhard’s talc could be reopened.
The company, which hasn’t disclosed any cost estimates over
talc-related asbestos cases, disputes Bevan’s assessment of
possible damages. “This is baseless speculation by plaintiffs’
lawyers,” spokeswoman Robin Rotenberg said in a statement. “As a
matter of policy, BASF does not speculate” on potential
liabilities.
Cahill spokeswoman Lynn Tellefsen declined to comment and
the firm said in a federal lawsuit that it behaved properly.
BASF replaced the firm in 2010.
Plaintiffs’ lawyers and legal experts vary in their
estimates of potential damages against BASF. “There’s no
question in my mind that it might cost BASF billions of dollars
to put these cases behind them,” said Erik Gordon, a University
of Michigan law professor. Others aren’t so sure. While Jonathan
George, an attorney at Waters, Kraus & Paul, which has sued the
company, said “there is potential substantial liability by
BASF,” he contends billions of dollars is “unrealistic.”
One case, which seeks class-action status, claims Engelhard
and Cahill engaged in fraud and fraudulent concealment by lying
about the talc, while hiding and destroying evidence. The
company and law firm have consistently denied wrongdoing in
court papers.
Another case, pending in state court in New Jersey, seeks
to force BASF to produce dozens of documents about the talc that
the company maintains are confidential.
The company “has not found that exposure to Engelhard’s
talc caused injury due to asbestos contamination,” Rotenberg
said.

Recent Litigation

BASF has said in recent litigation that some asbestos
existed in Engelhard’s talc but denied it caused injuries. The
talc was used in wall board, joint compound and auto body
filler. Tires workers used it to help grip products. But did
they inhale asbestos that came from Engelhard’s mine? BASF says
that will be hard to prove. The company also says it will be
hard to convince a judge to accept a class action.
“Plaintiffs face serious obstacles in attempting to certify
a class based on events that took place in thousands of
different asbestos cases litigated in different courts and at
different points in time by different lawyers,” BASF lawyers
said in a May 4 court filing.
Former workers blame Engelhard’s talc for ailments ranging
from mesothelioma, a cancer linked to asbestos, to lung
ailments. The average mesothelioma case is worth about $4
million, says Mark Lanier, a veteran Texas plaintiffs’ lawyer
who has tried more than 50 asbestos cases. Asbestos settlements
may ultimately cost corporations and insurers more than $265
billion, according to the Rand Institute, a non-profit research
group.

Dying Daughter

BASF first had to defend the litigation practices of
Engelhard and Cahill in 2009, when Donna Paduano sued in state
court in New Jersey over her mesothelioma. Paduano, who never
worked at Engelhard, claimed she was exposed to asbestos from
her father’s clothes or visits to his workplace.
A deposition by her father, former Engelhard scientist
David Swanson, triggered an investigation by lawyers who
uncovered test results showing the presence of asbestos in
Engelhard talc more than 25 years earlier. Paduano has since
died, as has Swanson, who had lung cancer but took no legal
action. Swanson’s testimony stunned Paduano’s lawyer,
Christopher Placitella.
“It was the first time any of us had heard” the company
knew its product contained asbestos, he said. “I was afraid that
this guy would turn out to be a nut and that my whole case would
go down the toilet.”
Instead, BASF settled the lawsuit with Paduano’s family
before her death, and Placitella began a years-long quest to
understand what Engelhard and Cahill did and what evidence they
may have hidden or destroyed.
The coverup began, Placitella claims, after a lawsuit filed
in 1979 blamed the mesothelioma death of a tire worker on
Engelhard talc. Engelhard settled in 1983 and the pre-trial
evidence, including testing that showed varying levels of
asbestos from a Vermont mine that the company ran since 1967,
was sealed -- a common practice in corporate litigation.

‘Document Retrieval’

The company closed the mine in 1983 and later issued a memo
entitled, “DOCUMENT RETRIEVAL -- DISCONTINUED OPERATIONS,”
instructing Engelhard staff to collect documents for discard
relating to several companies, including the talc mine’s
operator. The memo said the company would retain copies of
“documents to be preserved.”
In recent years, BASF and its new law firm, Kirkland &
Ellis LLP, have “expended an extraordinary amount of resources
to locate Engelhard documents -- including those maintained in a
warehouse by Cahill -- to find former Engelhard employees and to
learn the facts about the Engelhard legacy talc operations,”
BASF’s Rotenberg said. They provided “tens of thousands of
relevant documents” to plaintiffs’ lawyers, she said.
At the same time, BASF is opposing an application for
class-action status filed by the survivors of six people who
died of asbestos-related disease. And it’s fighting cases by
workers who claim that an auto-body filling compound they used
exposed them to asbestos from Engelhard’s talc. In a personal
injury case that ended in mistrial when the plaintiff died in
2013, BASF lawyers said that no Engelhard mine worker ever got
ill from the company’s asbestos.
Placitella filed a federal lawsuit in New Jersey against
BASF on behalf of six plaintiffs. Should the case receive class-
action status, he says he intends to share evidence of the
alleged cover-up with thousands of victims who may move to
reopen their asbestos cases in state courts ranging from
Pennsylvania to Kentucky. Those plaintiffs had previously sued,
but their cases were either thrown out or settled for nominal
sums.
A federal judge initially dismissed Placitella’s case on
procedural grounds, but in a reversal last year, a three-judge
appellate panel in Philadelphia revived his fraud and fraudulent
concealment claims.
In reinstating most of the plaintiffs’ claims, the panel
didn’t rule on the merits of the case, returning it to U.S.
district court for further proceedings. But it also spelled out
its disdain for the sort of conduct described in the complaint.
If indeed “they rigged the game from the beginning,” the
judges said, “how then can calculated false and misleading
statements serve the truth-seeking function of the litigation?
According to the complaint, BASF and Cahill were not
mischaracterizing the facts; they were creating them.”

For Related News and Information:
Top Stories:TOP
Bloomberg legal resources: BLAW
BASF earnings graph: BAS GY <Equity> FA ISBAR
BASF cash flow: BAS GY <Equity> FA CF

To contact the reporters on this story:
Jef Feeley in Wilmington, Delaware at +1-302-661-7616 or
jfeeley@bloomberg.net;
David Voreacos in federal court in Newark, New Jersey, at
+1-212-617-0768 or
dvoreacos@bloomberg.net
To contact the editors responsible for this story:
David Glovin at +1-212-617-4455 or
dglovin@bloomberg.net
Rick Schine, Heather Smith

>>> Lannett to acquire Kremers Urban Pharmaceuticals for $1.23 bln; expects the

--> LCI +18% After Hours

Lannett to acquire Kremers Urban Pharmaceuticals for $1.23 bln; expects the deal to be accretive to adjusted EPS in FY16 in the mid-high single digits and 20-25% in FY17

The co announced that it has signed a definitive agreement to purchase Kremers Urban Pharmaceuticals Inc., the U.S. specialty generic pharmaceuticals subsidiary of global biopharmaceuticals company UCB S.A., for $1.23 billion, plus potential contingency payments. Lannett believes the acquisition will be accretive to adjusted EPS in fiscal 2016 in the mid- to high-single digits and 20% to 25% in fiscal 2017. Lannett expects to receive a significant tax benefit with a value in excess of $100 million.
  • Lannett expects to fund the transaction with a combination of a fully committed term loan and cash on hand.
  • The transaction, subject to regulatory approval and other customary closing conditions, is expected to close in the fourth quarter of calendar 2015 and has been unanimously approved by the Boards of Directors of Lannett and UCB.

(CS) Spanish BAnks : Change of Analyst - few adjustments...Turning more cautious

We cut our 2015-17E earnings by 10-15% as we incorporate Q2 trends and
reflect what we see as a much more challenging revenue environment due to
(i) declining carry trade/trading income contributions, (ii) the removal of
mortgage floors, and (iii) intensified underlying NII pressures (owing to
insufficient loan growth momentum, accelerating loan spread compression and,
in our view, front book spreads on deposits having bottomed). Our new
numbers stand 10-15% below consensus.

We now forecast below-CoE RoTBV levels in 2017E (7-10% vs. 8-12%
previously), and see the likely political instability in Spain in 2H15 further
underpinning our negative stance.
On capital, and albeit expecting FL CET1 levels to fall within the European
average (11-13% in 2017E), we question the quality, with increasing concerns
regarding the validity of the DTA guarantees (190-570bps).

■ We downgrade Banco Sabadell to Underperform from Outperform (new
TP €1.7/sh), with the bank heavily impacted by the removal of floors and
declining trading/Treasury contributions (17-25% earnings cuts) – and with
solvency levels (11.8% in 2017E) heavily supported by DTAs.

■ We upgrade Bankia to Neutral (new TP €1.0/sh), which stands as the
biggest capital generator (160bps vs. 50-80bps for peers), though with
RoTBV prospects capped at 7.5-8% by the Treasury revenue loss.

■ Banco Popular (Underperform, new TP €3.0/sh) remains our least
preferred Spanish bank, with comparatively lower RoTBVs (7% in 2017E
vs. 8-9%) and solvency levels (11% vs. 11.8-12.9% for peers).

■ CaixaBank (Neutral, new TP €3.8/sh) is our preferred option, with
superior RoTBVs (9.6% vs. 7-8% in 2017E), optimal solvency (11.8% by
2017E) and a competitive dividend policy (4-5% yield in 2016-17E).
On a relative basis, within Southern Europe, we prefer ISP and UBI in Italy
(both Outperform).

>>> Asian Update Nikkei+1.38% Hang Seng closed Shanghaï closed

Asian Mid-session Update: AUD pressured again by slump in retail sales; IMF issues warning on China spillover risks


***Economic Data***
- (AU) AUSTRALIA JULY TRADE BALANCE: -A$2.5B V -A$3.2BE; 15TH STRAIGHT DEFICIT
- (AU) AUSTRALIA JULY RETAIL SALES M/M: -0.1% V +0.4%E; First decline in 14 months
- (AU) AUSTRALIA AUG AIG PERF OF SERVICES INDEX: 55.6 V 54.1 PRIOR; 3rd month of expansion
- (BR) BRAZIL CENTRAL BANK (BDB) LEAVES SELIC TARGET RATE UNCHANGED AT 14.25%, AS EXPECTED
- (JP) JAPAN AUG NIKKEI SERVICES PMI: 53.7 V 51.2 PRIOR; COMPOSITE PMI 52.9 V 51.5 PRIOR
- (KR) SOUTH KOREA Q2 FINAL GDP Q/Q: 0.3% V 0.3% PRELIM; Y/Y: 2.2% V 2.2% PRELIM
- (NZ) New Zealand Q2 Value of All Buildings Q/Q: 1.6% v 0.5%e

***Index Snapshot (as of 02:30 GMT)***
- Nikkei225 +1.2%, S&P/ASX -0.5%, Kospi +0.4%, Shanghai Composite closed, Hang Seng closed, Sept S&P500 +0.1% at 1,948

***Commodities/Fixed Income***
- Dec gold -0.1% at $1,132/oz, Oct crude oil -1.1% at $45.74/brl, Dec copper -0.2% at $2.32/lb
- (JP) Japan investors bought net ¥900.3B in foreign bonds v sold ¥277.2B in prior week; Foreign investors sold net ¥630.3B in Japan stocks v sold ¥462.8B in prior week

***Market Focal Points/FX***
- Volatility is compressed by the market holidays in Shanghai and Hong Kong, just as investors worldwide are awaiting updates from the ECB on Thursday morning and US non farm payrolls on Friday. The latter should either solidify the case for September Fed liftoff or bolster expectations of a climb down by the more hawkish members of the FOMC amid global market turmoil. In the Asia afternoon trade, main regional indices and S&P futures are little changed.

- In FX, key USD majors are also trapped in narrow ranges, with EUR/USD in a 20pip band above $1.12 and USD/JPY up only some 30pips to session-best 120.60 in spite of broad rally on Wall St. AUD is most volatile with a 60pip drop from the highs toward overnight 6-year lows around the $0.70 handle. Australia retail sale fell m/m for the first time in 14 months, while trade balance came in negative for the 15th straight month, albeit more narrow than expected. Exports to China, along with shipments of iron ore and coal were down marginally. On the plus side, Australia PM Abbott announced he still intends to put China FTA up for legislation before the end of this year.

- Excerpts leaked from tomorrow's interview with US Treasury Sec Lew revealed a predictably tougher rhetoric on China for its latest devaluation of Yuan, taking Beijing to task on the ramifications of its FX actions. Concurrently, US financial press report citing sources close to the IMF suggested the FX reform by the PBoC could make the IMF more inclined to include it in the SDR basket. Recall on Aug 19th, IMF board announced it would extend SDR rights basket through Sept of 2016, deferring on the decision for including Yuan until the end of this year. Also of note on the IMF, its report to G20 warned that China slowdown could be larger than expected and is among primary risks to global growth outlook. IMF also called for a "mutual" (coordinated) policy action to raise growth and mitigate risks, specifically asking for assistance from surplus economies such as Germany.

- BOJ's high-profile dissenter Kiuchi continued to question the effectiveness of open ended QQE. Consistently expressing a more hawkish view and voting for a taper of asset purchases, Kiuchi said the economy is recovering moderately, exports are picking up, and consumption will remain firm. Kiuchi also said policymakers should be more forward looking on medium and longer-term risks rather than short-term price developments and economy.

***Equities***
US equities / ADRs:
- LCI: Acquires Kremers Urban Pharmaceuticals for $1.23B; accretive to adjusted EPS in FY16 in the mid- to high-single digits and 20% to 25% in FY17; +19.8% afterhours
- EXPE: Expands partnership with AAL; +0.1% afterhours
- VRNT: Reports Q2 $0.70 v $0.68e, R$297.1M v $290Me; -6.9% afterhours
- FIVE: Reports Q2 $0.13 v $0.13e, R$182.8M v $184Me; -8.5% afterhours

Notable movers by sector:
- Consumer discretionary: Myer Holdings MYR.AU -21.7% (institutional offer); Harvey Norman HVN.AU -2.3% (acquisition)
- Industrials: Nidec Corp 6594.JP +3.0% (acquisitions); Mazda Motor 7261.JP +1.1% (Aug US sales)
- Technology: Toshiba Corporation 6502.JP +3.3% (speculation on earnings, divestment); Hon Hai 2317.TW -3.1% (speculation of investment in India); Acer 2353.TW +3.2% (speculation to raise notebook prices)

>>> US After Hours Summary: SEAC +4.5%, OOMA +2.2%, FIVE -9.5%,

After Hours Summary: SEAC +4.5%, OOMA +2.2%, FIVE -9.5%, VRNT -6.4% following earnings/guidance

After Hours Gainers:

Companies trading higher in after hours in reaction to earnings: SEAC +4.5%, OOMA +2.2%, OXM +0.1%

Companies trading higher in after hours in reaction to news: GERN +20.7% (announced publication of two papers in The New England Journal of Medicine that highlight the potential of imetelstat in hematologic malignancies), LCI +18.2% (to acquire Kremers Urban Pharmaceuticals for $1.23 bln; expects the deal to be accretive to adjusted EPS in FY16 in the mid-high single digits and 20-25% in FY17), ISR +6.2% (extended its international distribution agreement with Karlheinz Goehl-Medizintechnik Goehl), CERN +2.3% (formed strategic alliance with Glens Falls Hospital to connect the health system onto one electronic health record), TSLA +1.5% (CEO Elon Musk tweeted that Model 3 production will begin in ~2 years and will cost $35k), ATRO +0.9% (selected to supply the Passenger Service Units, on a new family of long-range Boeing (BA) 777X aircraft), NUE +0.8% (announced $900 mln share repurchase program)

After Hours Losers:

Companies trading lower in after hours in reaction to earnings: FIVE -9.5%, VRNT -6.4%, MIND -5.4%, CTLT -4.9%, PLNT -2.7%, ABM -1.3%, CFI -0.1%

Companies trading lower in after hours in reaction to news: RLI -2.2% (announced that President and COO Michael Stone will retire, effective Dec. 31, 2015; EVP Craig Kliethermes to assume that role at the beginning of 2016), DV -2.1% (disclosed that on August 28, 2015, it received a request for documents and information regarding published employment outcomes and earnings of DeVry University graduates from the Federal Student Aid office of the Department of Education), ETH -1.8% (co intends to raise up to $250 mln of long-term debt financing), HY -0.7% (co expects global lift truck markets expected to decline in H2 2015, with demand levels mixed by region)